miR-133a and miR-135a Regulate All-Trans Retinoic Acid-Mediated Differentiation in Pediatric Acute Myeloid Leukemia by Inhibiting CDX2 Translation and Serve as Prognostic Biomarkers
Technology in Cancer Research & Treatment · 2024
DOI: 10.1177/15330338241248576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Yu-Cai Cheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Leukemia, Myeloid, Acute, MicroRNAs, Tretinoin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Medical Science and Technology Research Foundation of Guangdong Province, China, the Shenzhen Fundamental Research Program.
Abstract (Originalsprache)
Background
Acute myeloid leukemia (AML) is a type of blood cancer characterized by excessive growth of immature myeloid cells. Unfortunately, the prognosis of pediatric AML remains unfavorable. It is imperative to further our understanding of the mechanisms underlying leukemogenesis and explore innovative therapeutic approaches to enhance overall disease outcomes for patients with this condition.
Methods
Quantitative reverse-transcription PCR was used to quantify the expression levels of microRNA (miR)-133a and miR-135a in 68 samples from 59 pediatric patients with AML. Dual-luciferase reporter transfection assay, Cell Counting Kit-8 assay, and western blot analysis were used to investigate the functions of miR-133a and miR-135a.
Results
Our study found that all-trans-retinoic acid (ATRA) promoted the expression of miR-133a and miR-135a in AML cells, inhibited caudal type homeobox 2 (CDX2) expression, and subsequently inhibited the proliferation of AML cells. Additionally, miR-133a and miR-135a were highly expressed in patients with complete remission and those with better survival. Conclusions: miR-133a and miR-135a may play an antioncogenic role in pediatric AML through the ATRA-miRNA133a/135a-CDX2 pathway. They hold promise as potentially favorable prognostic indicators and novel therapeutic targets for pediatric AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China.
- Department of Pediatrics, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
ORCID-Profile: Zhong Fan, Chun-Jin Peng
Förderung
- the Medical Science and Technology Research Foundation of Guangdong Province, China
- the Shenzhen Fundamental Research Program
Zitieren
APA
Cheng, Y. C., Fan, Z., Liang, C., Peng, C. J., Li, Y., Wang, L. N., Luo, J. S., Zhang, X. L., Liu, Y., & Zhang, L. D. (2024). miR-133a and miR-135a Regulate All-Trans Retinoic Acid-Mediated Differentiation in Pediatric Acute Myeloid Leukemia by Inhibiting CDX2 Translation and Serve as Prognostic Biomarkers. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241248576
Vancouver
Cheng YC, Fan Z, Liang C, Peng CJ, Li Y, Wang LN, et al. miR-133a and miR-135a Regulate All-Trans Retinoic Acid-Mediated Differentiation in Pediatric Acute Myeloid Leukemia by Inhibiting CDX2 Translation and Serve as Prognostic Biomarkers. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241248576
BibTeX
@article{Cheng2024,
author = {Cheng, Yu-Cai and Fan, Zhong and Liang, Cong and Peng, Chun-Jin and Li, Yu and Wang, Li-Na and Luo, Jie-Si and Zhang, Xiao-Li and Liu, Yong and Zhang, Li-Dan},
title = {miR-133a and miR-135a Regulate All-Trans Retinoic Acid-Mediated Differentiation in Pediatric Acute Myeloid Leukemia by Inhibiting CDX2 Translation and Serve as Prognostic Biomarkers},
journal = {Technology in Cancer Research & Treatment},
year = {2024},
doi = {10.1177/15330338241248576}
}
EUVIMED